166 related articles for article (PubMed ID: 36847413)
1. Real-world experience of tixagevimab-cilgavimab pre-exposure prophylaxis in orthotopic heart transplant recipients.
Ordaya EE; Higgins EM; Vergidis P; Razonable RR; Beam E
Transpl Infect Dis; 2023 Jun; 25(3):e14040. PubMed ID: 36847413
[TBL] [Abstract][Full Text] [Related]
2. Assessing the post hoc effectiveness of tixagevimab-cilgavimab for prevention of SARS-CoV-2 infections in solid organ transplant recipients.
Jordan SC; Joung SY; Wang M; Tran TA; Bravo M; Masoom H; Chang C; Mendez M; Sun N; Patel J; Kittleson M; Frias E; Prostko JC; Ebinger JE; Cheng S; Sobhani K
Transpl Infect Dis; 2024 Feb; 26(1):e14182. PubMed ID: 37885435
[TBL] [Abstract][Full Text] [Related]
3. A single-center review of pre-exposure prophylaxis with tixagevimab-cilgavimab in solid organ transplant recipients.
Morado F; Davoudi R; Kawewat-Ho P; Nanda N; Cartus R; Shaikh SA
Transpl Infect Dis; 2023 Aug; 25(4):e14086. PubMed ID: 37314092
[TBL] [Abstract][Full Text] [Related]
4. Pre-exposure Prophylaxis with Tixagevimab-cilgavimab did not Reduce Severity of COVID-19 in Lung Transplant Recipients with Breakthrough Infection.
Sindu D; Razia D; Grief K; Cherrier L; Omar A; Walia R; Tokman S
Transplant Direct; 2023 Jun; 9(6):e1485. PubMed ID: 37197016
[TBL] [Abstract][Full Text] [Related]
5. The Prevention of COVID-19 in High-Risk Patients Using Tixagevimab-Cilgavimab (Evusheld): Real-World Experience at a Large Academic Center.
Al-Obaidi MM; Gungor AB; Kurtin SE; Mathias AE; Tanriover B; Zangeneh TT
Am J Med; 2023 Jan; 136(1):96-99. PubMed ID: 36181789
[TBL] [Abstract][Full Text] [Related]
6. Tixagevimab/cilgavimab for the prevention of COVID-19 in solid organ transplant recipients.
Eribes E; Votruba C; Tinkham T; Huang A; Ilges D; Kunze K; Hudson M
Clin Transplant; 2024 Feb; 38(2):e15261. PubMed ID: 38375915
[TBL] [Abstract][Full Text] [Related]
7. Tixagevimab/cilgavimab pre-exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the omicron wave.
Al Jurdi A; Morena L; Cote M; Bethea E; Azzi J; Riella LV
Am J Transplant; 2022 Dec; 22(12):3130-3136. PubMed ID: 35727916
[TBL] [Abstract][Full Text] [Related]
8. COVID-19 Outcomes in Lung Transplant Recipients Following Pre-Exposure Prophylaxis With Tixagevimab-Cilgavimab During the Omicron BA.5 Surge: A Single Center Analysis.
Demolder S; Schaevers V; Lagrou K; De Munter P; Beeckmans H; Verleden GM; Godinas L; Dupont LJ; Van Bleyenbergh P; Lorent N; Vos R
Transpl Int; 2024; 37():12061. PubMed ID: 38328617
[TBL] [Abstract][Full Text] [Related]
9. Tixagevimab/cilgavimab prophylaxis against COVID-19 in solid organ transplant recipients: a systematic review and meta-analysis.
Khorramnia S; Navidi Z; Orandi A; Iravani MM; Orandi A; Malekabad ES; Moghadam SHP
Clin Transplant Res; 2024 Jun; 38(2):136-144. PubMed ID: 38904088
[TBL] [Abstract][Full Text] [Related]
10. Effects of Anti-COVID-19 Vaccination and Pre-Exposure Prophylaxis with Tixagevimab-Cilgavimab in Kidney and Liver Transplant Recipients.
Angelico R; Romano F; Coppola L; Materazzo M; Pedini D; Santicchia MS; Cacciola R; Toti L; Sarmati L; Tisone G
Medicina (Kaunas); 2023 Nov; 59(12):. PubMed ID: 38138204
[No Abstract] [Full Text] [Related]
11. Breakthrough SARS-CoV-2 infections among recipients of tixagevimab-cilgavimab prophylaxis: A citywide real-world effectiveness study.
Lendacki FR; Li L; Forrest GN; Jordan L; Zelinski C; Black SR; Ison MG; Seo JY
Transpl Infect Dis; 2024 Feb; 26(1):e14194. PubMed ID: 37987112
[TBL] [Abstract][Full Text] [Related]
12. Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld) for COVID-19 among 1112 severely immunocompromised patients.
Nguyen Y; Flahault A; Chavarot N; Melenotte C; Cheminant M; Deschamps P; Carlier N; Lafont E; Thomas M; Flamarion E; Lebeaux D; Charlier C; Rachline A; Guérin C; Ratiney R; Touchard J; Péré H; Rozenberg F; Lanternier F; Arlet JB; Avouac J; Boussaud V; Guillemain R; Vignon M; Thervet E; Scemla A; Weiss L; Mouthon L;
Clin Microbiol Infect; 2022 Dec; 28(12):1654.e1-1654.e4. PubMed ID: 35926762
[TBL] [Abstract][Full Text] [Related]
13. Genotypic and predicted phenotypic analysis of SARS-COV-2 Omicron subvariants in immunocompromised patients with COVID-19 following tixagevimab-cilgavimab prophylaxis.
Ordaya EE; Vergidis P; Razonable RR; Yao JD; Beam E
J Clin Virol; 2023 Mar; 160():105382. PubMed ID: 36731147
[TBL] [Abstract][Full Text] [Related]
14. SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19.
Hirsch C; Park YS; Piechotta V; Chai KL; Estcourt LJ; Monsef I; Salomon S; Wood EM; So-Osman C; McQuilten Z; Spinner CD; Malin JJ; Stegemann M; Skoetz N; Kreuzberger N
Cochrane Database Syst Rev; 2022 Jun; 6(6):CD014945. PubMed ID: 35713300
[TBL] [Abstract][Full Text] [Related]
15. Tixagevimab-Cilgavimab Decreases the Rate of SARS-CoV-2 Infection Among Solid Organ Transplant Recipients.
Sanayei AM; Montalvan A; Faria I; Ochalla J; Pavlakis M; Blair BM; Alonso CD; Curry M; Saberi B
Transplant Proc; 2023 Oct; 55(8):1784-1792. PubMed ID: 37661468
[TBL] [Abstract][Full Text] [Related]
16. Tixagevimab/cilgavimab for preventing COVID-19 during the Omicron surge: retrospective analysis of National Veterans Health Administration electronic data.
Young-Xu Y; Epstein L; Marconi VC; Davey V; Korves C; Zwain G; Smith J; Cunningham F; Bonomo RA; Ginde AA
mBio; 2023 Aug; 14(4):e0102423. PubMed ID: 37535398
[TBL] [Abstract][Full Text] [Related]
17. SARS-CoV-2 Pre-Exposure Prophylaxis with Sotrovimab and Tixagevimab/Cilgavimab in Immunocompromised Patients-A Single-Center Experience.
Totschnig D; Augustin M; Niculescu I; Laferl H; Jansen-Skoupy S; Lehmann C; Wenisch C; Zoufaly A
Viruses; 2022 Oct; 14(10):. PubMed ID: 36298832
[TBL] [Abstract][Full Text] [Related]
18. Preliminary Evidence of Good Safety Profile and Outcomes of Early Treatment with Tixagevimab/Cilgavimab Compared to Previously Employed Monoclonal Antibodies for COVID-19 in Immunocompromised Patients.
Lombardi A; Viero G; Villa S; Biscarini S; Palomba E; Azzarà C; Iannotti N; Mariani B; Genovese C; Tomasello M; Tonizzo A; Fava M; Valzano AG; Morlacchi LC; Donato MF; Castellano G; Cassin R; Carrabba M; Muscatello A; Gori A; Bandera A
Biomedicines; 2023 May; 11(6):. PubMed ID: 37371635
[TBL] [Abstract][Full Text] [Related]
19. Tixagevimab and cilgavimab use in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder during anti-CD20 treatment: A single-center experience.
Gelibter S; Pirro F; Saraceno L; Susani E; Moioli MC; Puoti M; Agostoni EC; Protti A
J Neuroimmunol; 2023 Oct; 383():578199. PubMed ID: 37717427
[TBL] [Abstract][Full Text] [Related]
20. Anti SARS-CoV-2 Monoclonal Antibodies in Pre-Exposure or Post-Exposure in No- or Weak Responder to Vaccine Kidney Transplant Recipients: Is One Strategy Better than Another?
Romero A; Laurent C; Lebourg L; Lemée V; Hanoy M; Le Roy F; Grange S; Lemoine M; Guerrot D; Bertrand D
Viruses; 2024 Feb; 16(3):. PubMed ID: 38543747
[No Abstract] [Full Text] [Related]
[Next] [New Search]
